Atossa Genetics, Inc.
Atossa Genetics,Inc is a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer.Using the company's patented, FDA-approved Mammary Aspirate Specimen Cytology Test (MASCT) System, a nurse or physician’s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 10 minutes. The NAF sample contains cells (cytology) and molecular diagnostic biomarkers that are useful in finding cancers and pre-cancerous changes, especially Atypical Ductal Hyperplasia (ADH), which confers a higher risk of developing breast cancer.The FDA has determined, based on clinical trial data, that the MASCT System can be used in the determination and/or differentiation of normal versus premalignant versus malignant cells. Cytology changes in NAF have been shown to occur up to eight years before changes can be picked up by mammography. The Company's name comes from Atossa, daughter of Cyrius the Great and wife of Darius I, the King of the Achaemenid Empire. In about 470 BC she became the first woman in recorded history to be diagnosed with breast cancer.
Contact Details
Office Address
Atossa Genetics, Inc.
4105 E Madison St, Suite 320
Seattle, WA, USA 98112
Phone: (206) 325-6086
Fax: (206) 325-6087
Executives
Chairman, President, and CEO
Steven C. Quay
CFO
Christopher Benjamin